NAS10027,088+1.72%S&P7,415+0.84%GOLD$4,061−1.27%BTC$75,685−0.34%VIX24.44−13.27%latest tape · as of 16:01 UTC
The Screen · Healthcare · Biotechnology
PLXProtalix BioTherapeutics Inc
PLX · NYSE AMERICAN · USD · Market cap $200M · 226 employees
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.09, read 2026-11-05
Ethical passes the values gate
Price2.51 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-10-25Read Markdown2.70-7.0% to today ✓Accumulation gives way to Markdown first Markdown read since October
2026-10-18Read Accumulation2.70-7.0% to today Markdown gives way to Accumulation
2026-10-11Read Markdown2.70-7.0% to today ✓Accumulation gives way to Markdown
2026-10-02Read Accumulation2.75-8.7% to today Markup gives way to Accumulation after a 6% rise in 3 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Protalix BioTherapeutics Inc holds its Markdown at $2.51. Consolidating, no directional conviction, held for 138 days.
As held on the ledger · 2026-11-05
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 138 days
Price at the screen
$2.51
Valuation
10.78 trailing · 4.00 forward price to earnings
Values screen
PASS· score 70.0
Beta
-0.09
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.10%
Below 33%
Interest-bearing debt is just 10.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
18.94%
Below 33%
Cash held in interest-bearing accounts and securities is 18.9% of assets, under the one-third limit.
Pass
Receivables
28.56%
Below 49%
Money owed to the company is 28.6% of assets, under the 49% limit.
Pass
Revenue purity
2.05%
Below 5%
Only 2.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Protalix BioTherapeutics clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 10%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PLX's ethical verdict changes
Today PLX passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. The analyst targets sit too far from the price to cross-check it; our model's value is 4.45x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PLX trades on NYSE AMERICAN. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markdown$2.59-4.1%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 6% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-25Markdown · changed$2.70+0.0%Entry 9
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 10% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-18Accumulation · changed$2.70+0.0%Entry 8
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-11Markdown · changed$2.70-1.8%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-02Accumulation · changed$2.75+6.2%Entry 6
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-09-09Markup · changed$2.59+8.8%Entry 5
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-08-08Accumulation$2.38+13.9%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 13.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-07-18Accumulation$2.09+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are up 24%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-07-03Accumulation$2.09+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$2.09Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.